Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 10/20 | 0.46 |
| ▸ | TNKS | O95271 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | ATR | Q13535 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21463400 | 1.00 | MCHR1 (0.46) | MCHR1TNKSPDGFRBFGFR1KDR | |
| SCHEMBL30615420 | 1.00 | MCHR1 (0.46) | MCHR1TNKSPDGFRBFGFR1KDR | |
| SCHEMBL30615332 | 0.84 | TNKS (0.45) | MCHR1TNKS | |
| SCHEMBL30615602 | 0.84 | TNKS (0.45) | MCHR1TNKS | |
| SCHEMBL21464096 | 0.84 | TNKS (0.45) | MCHR1TNKS | |
| SCHEMBL21464106 | 0.84 | TNKS (0.45) | MCHR1TNKS | |
| SCHEMBL21464095 | 0.84 | TNKS (0.45) | MCHR1TNKS | |
| SCHEMBL28488291 | 0.80 | TNKS (0.48) | TNKSPIK3CA | |
| SCHEMBL28495324 | 0.79 | TNKS (0.48) | TNKSFGFR1 | |
| SCHEMBL28488276 | 0.79 | TNKS (0.48) | TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| CN-111868037-B | Fused cyclic urea derivatives as CRHR2 antagonists | 拉夸里亚创药株式会社 | 2023-10-13 | — | — | CN | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-03-18 | — | — | US | disclosed |
| EP-3774739-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RaQualia Pharma Inc. (JP) | 2021-02-17 | — | — | EP | disclosed |
| CN-111868037-A | Fused cyclic urea derivatives as CRHR2 antagonists | 拉夸里亚创药株式会社 | 2020-10-30 | — | — | CN | disclosed |
| WO-2019198692-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | MCHR1 50/4885TNKS 4519/4885PDGFRB 4763/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | MCHR1 50/4885TNKS 4519/4885PDGFRB 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.